REGN
REGENERON PHARMACEUTICALS, INC.
Nasdaq: REGN · Tarrytown, NY · Healthcare
$747.36-2.05 (-0.27%)Closed
Market Cap$70.56B
Cash$8.61Bmost recent
Runwayprofitable
P/E (TTM)18.0EPS $41.48
52-Wk Range$476.49 – $821.11
Avg Volume610.3K3-month
Price & Trading Activity

Daily close with catalyst overlays and trading volume

$747.36-16.4%
Pipeline

Drug candidates sponsored by REGENERON PHARMACEUTICALS · ClinicalTrials.gov

66 drugs · 100 trials
PhaseDrug / CandidateIndicationsStatusNext CompletionTrials
Phase 4dupilumab
Asthma+11 more
Recruiting
2026-12-31
15
Phase 3Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)
Branch Retinal Vein Occlusion
Completed
2013-08past
1
Phase 3LMT (atorvastatin, simvastatin, or rosuvastatin)
Heterozygous Familial Hypercholesterolemia
Completed
2014-05past
1
Phase 2Fasinumab
Low Back Pain
Completed
2017-02-03past
1
Phase 3REGN2810/ipi
Non-small Cell Lung Cancer
Terminated
2021-07-29past
1
Phase 3REGN3918
Paroxysmal Nocturnal Hemoglobinuria+1 more
Completed
2022-04-07past
2
Phase 2aflibercept
Diabetic Macular Edema+2 more
Completed
2022-05-30past
1
Phase 3REGN2810
Non-small Cell Lung Cancer
Completed
2025-02-27past
1
Phase 3REGN1908
Allergic Conjunctivitis
Completed
2025-05-10past
1
Phase 3Pozelimab + Cemdisiran
Generalized Myasthenia Gravis
Active, not recruiting
2025-07-08past
1
Phase 3Aflibercept 8 mg
Neovascular Age-Related Macular Degeneration+1 more
Active, not recruiting
2025-08-26past
1
Phase 3Cemiplimab
Squamous Cell Carcinoma (SCC)+6 more
Active, not recruiting
2026-05-31
6
Phase 3Odronextamab
Diffuse Large B-cell Lymphoma (DLBCL)+1 more
Active, not recruiting
2026-07-06
2
Phase 3Ravulizumab
Paroxysmal Nocturnal Hemoglobinuria
Recruiting
2027-01-28
1
Phase 3Mibavademab
Generalized Lipodystrophy
Recruiting
2028-05-19
1
Phase 3Pozelimab
Paroxysmal Nocturnal Hemoglobinuria+2 more
Recruiting
2029-11-07
5
Phase 2fianlimab
Advanced Non-Small Cell Lung Cancer
Active, not recruiting
2030-03-11
1
Phase 2Rilonacept
Gout
Completed
2008-10past
1
Phase 1REGN846
Pruritus+1 more
Terminated
2013-04past
1
Phase 2REGN1033 (SAR391786)
Sarcopenia
Completed
2015-01past
1
Phase 2REGN2176-3
Neovascular Age-Related Macular Degeneration+1 more
Completed
2016-08-17past
2
Phase 2Alirocumab
Hypercholesterolemia+1 more
Completed
2016-12-22past
2
Phase 2REGN910-3
Neovascular Age-Related Macular Degeneration
Completed
2017-10-03past
1
Phase 2REGN10933+REGN10987 combination therapy
COVID-19
Completed
2021-05-07past
3
Phase 2SDREGN2810
Advanced Non-Small Cell Lung Carcinoma
Terminated
2021-10-27past
1
Phase 2Placebo
Generalized Lipodystrophy+1 more
Completed
2022-01-05past
2
Phase 2casirivimab+imdevimab
Healthy+2 more
Completed
2022-11-21past
2
Phase 2vidutolimod
Merkel Cell Carcinoma+5 more
Terminated
2024-10-31past
1
Phase 1Ubamatamab
Recurrent Ovarian Cancer+5 more
Recruiting
2026-02-01past
1
Phase 2REGN7544
Sepsis-Induced Hypotension+1 more
Recruiting
2026-03-20past
2
Phase 2Trevogrumab-Part A
Obesity
Active, not recruiting
2026-05-18
1
Phase 1REGN7075
Advanced Solid Tumors
Recruiting
2026-08-19
1
Phase 2ALN-HSD
Metabolic Dysfunction-associated Steatohepatitis (MASH)
Recruiting
2027-09-08
1
Phase 2ALN-ANG3
Diabetic Kidney Disease (DKD)
Recruiting
2027-09-24
1
Phase 2BNT116
Advanced Non-Small Cell Lung Cancer
Active, not recruiting
2028-01-26
1
Phase 1Vonsetamig
Chronic Kidney Disease (CKD)+1 more
Recruiting
2028-07-23
2
Phase 1ALN-SOD
Amyotrophic Lateral Sclerosis (ALS)+1 more
Recruiting
2031-06-05
1
Phase 1REGN5093
NSCLC
Recruiting
2032-04-22
1
Phase 1ziv-aflibercept
Lymphoma+1 more
Completed
2002-03past
1
Phase 1VEGF Trap-Eye
Diabetic Macular Edema
Completed
2006-08past
1
Phase 1REGN727
Healthy
Completed
2010-10past
1
Phase 1REGN668: Injection Rate 1
Healthy
Completed
2012-02past
1
Phase 1REGN668
Dermatitis
Completed
2012-07past
1
Phase 1REGN2222(SAR438584)
Healthy Volunteers
Completed
2015-02past
1
Phase 1Sarilumab
Rheumatoid Arthritis
Completed
2015-04past
1
Phase 1REGN1908-1909
Allergy
Completed
2015-12-31past
2
Phase 1REGN2222
Healthy Volunteers
Completed
2016-09past
1
Phase 1REGN5069
Healthy Volunteer
Completed
2019-09-30past
1
Phase 1Fasinumab AI
Osteoarthritis, Knee+1 more
Completed
2020-01-15past
1
Phase 1REGN4461
Healthy Volunteers
Completed
2020-01-27past
1
Phase 1REGN6490
Healthy Volunteer
Terminated
2021-05-28past
1
Phase 189Zr˗DFO˗REGN3504
Advanced PD-L1 Positive Malignancies
Terminated
2021-07-08past
1
Phase 1REGN10933+REGN10987
Healthy+1 more
Completed
2021-11-22past
1
Phase 1CMP-001
Melanoma
Completed
2022-12-06past
1
Phase 1BPX-601
Metastatic Castration-resistant Prostate Cancer+1 more
Terminated
2023-03-14past
1
Phase 1REGN3767
Malignancies
Completed
2024-04-02past
1
Phase 1ALN-PNP
Nonalcoholic Fatty Liver Disease (NAFLD)+2 more
Completed
2025-07-07past
1
Phase 1bbT369
Diffuse Large B Cell Lymphoma (DLBCL)
Terminated
2025-09-19past
1
Phase 1REGN9533
Healthy Volunteer
Completed
2026-01-29past
1
Phase 1ALN-F1202
Healthy Volunteer
Active, not recruiting
2026-07-30
1
Phase 189Zr˗DFO˗REGN5054
Advanced Solid Tumor+1 more
Recruiting
2027-01-06
1
Phase 1REGN22044
Healthy Volunteer
Not yet recruiting
2027-05-27
1
N/AUnnamed
Rheumatoid Arthritis
Completed
2010-12past
1
N/AALIROCUMAB SAR236553 (REGN727)
Hypercholesterolemia
Terminated
2020-09-04past
1
N/AUnnamed
Hemophilia B
Active, not recruiting
2026-05-21
1
N/AREGN5458
Multiple Myeloma
Approved For Marketing—1
Valuation

Risk-adjusted NPV

Loading pipeline…
Peer comparison

Cohort check

Large-cap biotech · 5 tickers
Loading peers…
Cells tinted green are top-ranked in the cohort, red are worst-ranked.